Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2023-06-09 Capital/Financing Update
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 95% confidence The document is a Free Writing Prospectus (FWP) filed pursuant to Rule 433, relating to a public offering of securities by Aytu BioPharma, Inc. It details the pricing of an at-the-market equity offering, the appointment of a new director, terms of warrants, and the use of proceeds. It references a Registration Statement on Form S-1 and a preliminary prospectus. The content focuses on capital raising activities, financing terms, and related corporate governance changes (new director appointment). There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a full audit report, earnings release, or investor presentation. It is a detailed update on financing and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2023-06-09 English
Regulatory Filings 2023
Regulatory Filings
2023-06-09 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 for a proposed offering by Aytu Biopharma, Inc. It discusses the request for acceleration of the registration statement's effectiveness and compliance with distribution rules for the preliminary prospectus. The content is related to a capital raising process and regulatory compliance but does not contain financial statements, earnings data, or detailed report content. The document length is short (1474 characters) and is a formal communication rather than a report or presentation. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-06-07 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from Aytu Biopharma, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a formal communication related to a securities registration process, not a financial report or detailed filing. The document length is short (1241 characters) and it is a correspondence letter, not the registration statement itself. This fits the category of a Regulatory Filing (RNS), which includes general regulatory announcements and compliance documents that do not fit other specific categories.
2023-06-07 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Free Writing Prospectus (FWP) filed pursuant to Rule 433, relating to a preliminary prospectus and registration statement for a public offering of securities by Aytu Biopharma, Inc. It contains detailed information about the company's financial performance, growth drivers, market dynamics, and strategic realignment, all in the context of a securities offering. The presence of terms like 'Registration Statement on Form S-1', 'prospectus', and references to SEC filings for the offering clearly indicate this is a capital raising document. This type of document is best classified as a Capital/Financing Update (CAP), as it provides updates on the company's fundraising and securities offering activities rather than being a full annual or quarterly report, earnings release, or other filing types.
2023-06-06 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A, which is a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is used for registering securities for public offering, including detailed information about the company, the offering, risk factors, use of proceeds, and other disclosures. The text includes references to the registration statement number, the offering process, placement agent fees, and other details typical of a securities registration prospectus. This is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to a securities offering. According to the provided filing definitions, none explicitly mention Form S-1 or registration statements. The closest relevant category is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. Since this document is a registration statement for a securities offering, it fits best under Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the appropriate classification is CAP with high confidence.
2023-06-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.